Semaglutide for lymphoma patients having a stem cell transplant
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests whether a medicine called semaglutide (used for diabetes and weight loss) can help people with lymphoma recover better after a stem cell transplant using their own cells. It is for patients who are scheduled for this transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of lymphoma that has come back (relapsed diffuse large B-cell lymphoma or follicular lymphoma) and you are scheduled for a stem cell transplant using your own cells.
- Your body mass index (BMI) is 18.5 or higher.
- You are able to care for yourself (ECOG score 0–2).
- You do not have diabetes, pancreatitis, inflammatory bowel disease, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
This trial tests the drug glofitamab given before or after a stem cell transplant for patients whose B-cell lymphoma has returned or not improved. It aims to see if glofitamab can help make the transplant more effective or prevent the cancer from coming back.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Chemotherapeutic Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.